(1)(2) (3) (4) Vol. 21 No
|
|
- ちかこ おおばま
- 7 years ago
- Views:
Transcription
1 201980Japan as number one 21American as number one Vol. 21 No
2 (1)(2) (3) (4) Vol. 21 No
3 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS Vol. 21 No
4 Vol. 21 No
5 b(hp) g/m mb(hp) g/m Harper g/m m g/m g/m 6 Vol. 21 No
6 1510g/m // 1510g/m 10g/m * / / / Vol. 21 No
7 17 g/m g/m g/m (H3N2) Vol. 21 No
8 . 10 MDCK CPE -RNA EIA Directigen Flu A R Becton DickinsonUSA. HI test CF test Vol. 21 No
9 7080 1,2,3 Howells CH, et allancet i ,1975 Patriaca PA, et aljama ,1985 Gross PA, et alarch Intern Med ,1988 Govaert ME,et al,jama 272: , p / 55:2751,'97 5 /9223/213p<0.1 72:60,'98 4 /86 12/123p< :1009,'98 4 /16 49/84p< R mg/ -167o OTC,, BMY PM-523 RNA RNAPB GG-167 Ro GS Vol. 21 No
10 Harper,G.J.Airborne micro-organisms survival tests with four viruses. J.Hyg. Camb Therapeutic Research Vol. 21 No
11 13 Vol. 21 No TG VLDL LDLHDL TG LPL TG VLDL VLDLTG IDLIDL TG TGHTGL TG LDLLDL LDL LDL HDLHDL VLDL HDL LDL
12 14 Vol. 21 No LDL LDL- LDL-C 100 LDL LDL-C TG 300mg/dl 100 LDL TG HDL- HDL-C LDL-C VLDL C- HDL- SLE
13 15 Vol. 21 No TG HDL-C TG TG HDL-C LPL VLDL TG HDL-C TG TG TG HDL-C TG HDL-CTG LPL HDL-C TG VLDLTG HDL-C LDL-C LDL-CHDL-C LDL-CHDL-C TG TG TG LDL LDL LDL LDL LDL
14 16 Vol. 21 No LDL HDL TG TGHDL VLDLTG HDLTG HDL LDL LDL VLDLTG IDL TG silent disease 75 X TG1,000mg/dl mm 200mg/dl LDL-C140mg/dl TG150mg/dl TGHDL-C40mg/dl HDL-C LDL-C 200mg/dl120mg/dl mg/dl120139mg/dl TGHDL-C 12 WHO ab
15 a b VLDL -VLDL or LDL VLDL LDL IDL VLDL TC TC TC TC TCor TC TG TG TG TG TG TG g E C mg SM P mg SMP g 300mg 25g 40g P/S1.02.0W-3 W-3 TGVLDL 200mg 5025g 40g 40 P/S New York Anticoronary Club Study, Finnish Mental Hospital Study, Los Angeles Veterans Administration Study LDL-C TGHDL- C Vol. 21 No
16 1,200mg 1,5002,250mg - 300mg A 600mg EPL 1,500mg mg MDS 1,800mg mg 23g 6001,200mg 7501,500mg B 7501,500mg 7501,500mg 1,500mg 600mg 400mg 300mg * CI mg EPA 1,8002,700mg 812g1827g 3g 5001,000mg HMG-CoA C 1020mg 510mg 2060mg mg * CI Vol. 21 No
17 19 Vol. 21 No A BTG TG C Evidence based medicine HMG-CoA mg HMG-CoA EPATG
18 EPA 1,800mg EPA 100mg 200mg EPA Lipid Research Clinics Coronary Primary Prevention TrialLRC-CPPT Helsinki Heart StudyHHS West of Scotland Coronary Prevention StudyWOSCOPSAir Force/Texas Coronary Atherosclerosis Prevention StudyAFCAPS/Tex CAPS Pravastatin Multinational Study PMNSCholesterol and Recurrent Events CARELong-Term Intervention with Pravastatin in Ischaemic DiseaseLIPID Scandinavian Simvastatin Survival Study4S 20 Vol. 21 No
19 21 Vol. 21 No AA 25 kg 1000mg 250mg mg 10mg mg 10mg 10mg mg mg mg mg 1.3mg mg mg mg 50mg 340mg mg
20 22 Vol. 21 No kg1000mg 1000mg25 ph8.5 U
21 23 Vol. 21 No
22 24 Vol. 21 No
23 0428(74) (74) (74) (85) (83) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (86) (85) (85) (85) (85) (83) (83) (83) (83) (83) (83) (598) (598) (598) (597) (77) (76) (91) (91) (734) (734) (796) (774) (3401) (3404) (3376) (3844) (3781)0265 Vol. 21 No
24 03(3781) (3471) (3491) (3712) (3713) (3751) (3768) (3758) (3751) (3729) (3731) (3753) (3753) (3734) (3753) (3732) (3731) (3739)5527 Na,Ca,Mg 03(3742) (3731) (5711)1126 NU-LAND 03(3739) (3744)1822 HM 03(3730)2665 Na 03(3700) (3483) (3413) (3702) (3707) (3467) (3339) (3623) (3631) (3644) (3689) (3680) (2) (2) (2) (2) (2) (2) (2) (2) (5) (5) (5) (5) (5) (8) Vol. 21 No
25 04992(8) (5) (5) (8) (8) (2) (2) (2) (2)1121 BOOM 04996(2) (2)1121 Vol. 21 No
26 28 Vol. 21 No PR AA
27 ph B2202-(1) Vol. 21 No
28 30 Vol. 21 No
29 31 Vol. 21 No cm cm 1/960kg kg
30 Percutaneous Absorption of 14 CO2 during 14 CO2-Bathing in Rabbits B Vol. 21 No
31 JR Vol. 21 No
32 35 Vol. 21 No cm200 cm m 2.5m 11 11
33 stalactite stalactitestalagmite calcium carbonate, CaCO3calcite cm 0.5cm marblelime stone aragonite chalk 36 Vol. 21 No
34 CaCl2 NaCO3 precipitated calcium carbonate Balanophyllia sp. Stalactite 15g Vol. 21 No
35 1520g Vol. 21 No
36 ddddddddddddddddddddddddddddddddddddddddddddd ddddddddddddddddddddddddddddddddddddddddddddd Vol. 21 No
37 42 Vol. 21 No
38 C1 C3b C3aC5a C9 Vol. 21 No
39 44 Vol. 21 No
40 Vol. 21 No
41 BCG Vol. 21 No
42 Fc Vol. 21 No
43 Vol. 21 No
44 Vol. 21 No
45 51 Vol. 21 No
46 ,813, ,621, ,067, ,622, ,348, ,846, ,290, ,971,044 18,859,400 18,859,000 16,800,000 13,177,173 27,406,000 27,406,000 84,384,000 84,384,000 6,000 1,100,000 20,440,000 20,377,671 2,900,000 4,402,657 2, ,015,118 75,488,074 3,364,268 0 A 635,347, ,723,613 B 635,347, ,531,983 CAB 0 37,191,630 8,415,000 6,514,349 4,900,000 3,343,861 12,450,000 10,056, ,000 2,803,379 1,350,000 1,511,802 7,510,000 7,554,054 10,750,000 8,246,017 2,700,000 3,733,386 1,800,000 1,729, , , ,996,000 28,329, ,700,000 6,661, ,652,000 18,745, ,530,000 1,874, , , , , ,000,000 1,000, ,870,250 53,353, ,000,000 2,919, ,000,000 1,584, ,000,000 3,699, ,200,000 1,857, ,000,000 9,559, , , , , , , ,896,000 28,541, ,886, ,588, ,300 6,570 PEM H Vol. 21 No
47 53 Vol. 21 No
48 54 Vol. 21 No B A 2A2B A1B2070 2A GE
49 55 Vol. 21 No OTC OTC 700
50 56 Vol. 21 No OTC
51 57 Vol. 21 No NHK
52 58 Vol. 21 No
53 59 Vol. 21 No ,3134,
54 FAX ,000 SST H TEL FAX ,000 RAD-AR TEL Vol. 21 No FAX OTC FAX ,000 5,0002, TDM TDMTDM TEL FAX ,000 15, FAX
55 63 Vol. 21 No
56 64 Vol. 21 No PRNHK 9/2110/1911/
57 65 Vol. 21 No , in TOKYO HIV , , ,
58 , Vol. 21 No
20-121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
More informationuntitled
21 + TC : Toatal Choelesterol TGtriglyceride CE : cholesterol ester VLDLvery low density lipoprotein IDLintermediate density lipoprotein LDL low density lipoprotein HDL high density lipoprotein FFAfree
More informationuntitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
More information[] 1
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
More informationuntitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
More information07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
More informationuntitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
More information紀要No.9_006王_CS.indd
1 2 3 4 5 87 9 2009 1937.1 6 1937.1 2 1937.3 1937.9 73 1941.6 77 1941.10 27 1943.9 1943.10 1944.12 1946.12 1947.1 5 1948.4 L 1949.9 10 1950.10 1953.1 1953.12 1956.5.16 1956.6 1966.9 30 1966.10 1967.4 1967.9
More informationA B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
More information函館市_絵で見てわかる
70 75 26 2 27 1 2 3 4 5 6 7 8 9 4 6 6 6 8 10 10 10 10 12 21 21 22 26 28 30 32 34 36 2 3 70 75 701 28 75 6575 7075 28 75 3 4 5 75 65 26 28 75 65 75 1 1 70 7075 2 2 2 1 260 90 210 18 9012 160 18 100 183
More information04菊池氏.indd
KIKUCHI Sakae 1 1 1899 32 2000 1966 1.58 1990 1.57 2000.15 2 32 13 2 3 4 18 39.6 25 216,974 106,594 110,380 12 22 5 4.72 12 6 25 33 60 90 25 35 23 24 3 25 7 25 35 45 2 2002.9 4 1925 2003 1997 8 1975 25
More information2
1 2 3 TG T-cho 4 TG 10 Triglyceride (mg/dl) 400 350 300 250 200 150 T-cho 100 50 B 0 B B B Pre 2 4 6 8 10 12 After feeding (hr) B B B 5 HPLC 6 HPLC 152-0034 1-5-22-201 Tel. 03-5731-3630 / Fax. 03-5731-3631
More information3675-433897418-1.pdf
A : : : : : : : : : : PR PR NHK 2 PR PR 3 1954 7 4 5 9 12,000 12 100 2 2 11 4 5 6 7 / PR 8 9 10 11 1952 ( ) 2008 2009 2012 NHK km m m 12 m km km kg kg 13 % 14 15 1959 5 20 8 17100kg 400kg How much? 60
More informationほんぶん-第6章.indd
m,m ...,,,..... BCG - /.... T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S
More information1 2
( ) ( ) ( ) 1 2 59 2 21 24 275 43 3 26 486 103 27 28 98 105 104 99 1 48 25 29 72 14 33 11-10 3 11 8 14,663 4 8 1 6.0 8 1 0.7 11-6 27 19 22 71 5 12 22 12 1,356 6 4,397 3 4 11 8 9 5 10 27 17 6 12 22 9
More informationuntitled
-1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86
More information1 2 3 4 10 5 30 87 50 20 3 7 2 2 6 3 70 7 5 10 20 20 30 14 5 1,000 24 112 2 3 1 8 110 9 JR 10 110 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 25 30 31 32 25 A 33 B C D E F G PR PR or 34 35
More information糖尿病薬の保険調剤留意事項など
E-mail; west@gifu-shiya k u.ne t supported by 2 Road traffic accident risk in patients with diabetes mellitus receiving blood glucose-lowering drugs. Prospective follow-up study S. Skurtveit*, H. Strøm*,
More information<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
More information6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
More information180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
More informationVol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11
Vol.170 2004.9.9 9 17 9 17 1000 8 10 9 17 14:00 17:00 30 28 Vol.171 2004.9.15 14 100 5 10 15 52 53 55 1 7 55 58 63 3 26 53 3 6 9 2 3 6 9 6 52 53 55 3 9 5 1 7 10 14 4 12 8 11 9.17 10 15 38 51 53 55 6 2
More information....
2030 2 Vol. 22 No. 32000 1/2 EE F FAF 60E 1970 40 25FIP 1995 503cx 60 10M5 Vol. 22 No. 32000 3 carpal tunnel syndrome entrapment neuropathy cm 4 Vol. 22 No. 32000 5 Vol. 22 No. 32000 10 2- microglobulin
More informationa a b a b c d e R c d e A a b e a b a b c d a b c d e f a M a b f d a M b a b a M b a M b M M M R M a M b M c a M a R b A a b b a CF a b c a b a M b a b M a M b c a A b a b M b a A b a M b C a M C a M
More information12 12 343 936 PR 2 3 11 11 11 12 12 12 14 15 15 15 16 20 20 21 23 23 23 24 25 10 4 26 26 27 27 27 28 2000 28 28 28 29 30 30 30 31 31 32 32 34 34 35 35 36 36 36 36 37 37 37 37 40 41 5 6 NHK 14 4 7 () NHK
More information高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
More information労働法総論講義(2・完)
173 174 175 176 .... 177 ............ NHK NHK.. NHK.................. 178 ........ 179 180 181 182 183 .. 184 185 186 187 .............. 188 .. 189 .. 190 .. 191 192 193 .. 194 195 196 .............. 197
More information新入_本文.smd
52 28 220 28 4 1 017-777-1511 2 2 8 2 9 8 9 47.2% 12.8% 11.5% 6.0% 4 2 (49.6%)(13.0%) (14.7%) (7.4%)(8.4%) (52.3%)(9.1%) (11.4%) (10.0%) 33.0% 23.4% 15.6% 9.6% (26.0%) (18.3%) (46.5%) (30.0%) (20.0%) 2
More information10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
More information本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
More informationSample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
More informationBAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
More informationMNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2
2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.
More information0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
More information10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
More information緑化計画作成の手引き 26年4月版
http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm
More information第4回クッキーテスト研究会研究報告集(PDF)
2007 H19.8 2007 5 26 () 2 3 7 9 12 14 15 18 25 29 1 2 () (g g kcal) mg/dl.mg/dl ( U/mlhr).(mg/dl*U/ml) 50.2 158.6cm 70.7kg 28.1kg/ 92.5cm ( ) () ( ) (.(.-.)g/ml.(-.) g/ml ((MS) MS MS cm 2 MS () 3 4 122/74
More information“÷Œò›ï46
46 1 1 50.1 2 34 kgkg100 XCT100cm 2 2005 1100cm 2 85 cm90 cm 5 5 1 2 6OSCE OSCE 7 8 9 13 14 16 17 17 20 18 19 22 23 25 19 26 6 BMI 4.0g/ml 6 2 7 RIA EIA 8 3.10.3 ng/ml 7.91.2 ng/ml 2 7401620 2002 9 11
More information報告書
1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015
More information() 2
1 () 2 2 4 3 6,500 4 5 2 6 A B A B A B A B - A B 7 8 A B A B A B 9 JR JR 10 11 6 5 12 17 6 13 14 B A A B A B A B 2 1 8 15 8 16 17 9 18 3 4 5 mm mm 19 2 20 3 6 7 11 12 13 14 18 4 3 2 1 21 3 12 13 14 16
More information2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
More information36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
More informationJournal Club 2017/05/30 Tomohiro Matsumoto PGY-2
Journal Club 2017/05/30 Tomohiro Matsumoto PGY-2 本 の論 March 21, 2017 2 Introduc)on 3 : (CIN) 3 25% 44µmol/L(0.5mg/dL) CIN 4 European Society of Urogenital Radiology. ESUR guidelines on contrast media,
More information21 60 Vol. 21 No
3040 90 2 Vol. 21 No. 81999 21 60 Vol. 21 No. 81999 3 4444444444444444444444444444444444444444444444444444444 1830 10 12 1010 18 80 32 4 Vol. 21 No. 81999 Vol. 21 No. 81999 5 6 Vol. 21 No. 81999 Vol. 21
More informationuntitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
More information- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More information21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
More informationBMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
More informationuntitled
HCV 150 HCV 13 3 13 4 13 8 14 2 14 2 14 8 15 3 15 8 17 3 7 8 18 3 ----- i Q1 1 Q2 1 Q3 1 Q4 2 Q5 3 Q6 3 Q7 3 Q8 4 Q9 4 Q10 : 5 6 Q1 6 Q2 7 Q3 7 8 Q4 8 Q5HCV 8 Q6HCV 9 Q7HCV 9 Q8NAT 10 Q9 10 Q10 11 Q11
More information星医会00表紙.pdf
H A,, , ,,, Facebook PSP PSP in situ hybridization New York Bronx Veterans Administration Hospital, Alcohol Research and Treatment Center demanding education e-ducare S. M. McCann Proc. Natl. Acad.
More information00.O.t.qxd
... a... s...... a... s... 3 d... 4 f... 5 g... h... 7 j... 7... 9 aco... 9 smag... 5 d MAG... 9...... a... s... d... f... 3 g... 4 h... 4... a... s... 5 mm mm..4...0 0. 0..0..0..3 3. 4.5 0 450A 00 350A
More informationQ A ワークショップ 肥 満 症 Q&A パート1 概 念 成 因 合 併 症 Q1: 長 谷 川 和 田 LDL HDL EPA LDL HDL EPA HDL CRP () 和 田 中 村 相 澤 Q2:HbA1C 長 谷 川 佐 藤 m
Vol. 17 No. 1 2011 トピック 日 本 肥 満 学 会 主 催 第 8 回 肥 満 症 サマーセミナー 特 集 日 本 肥 満 学 会 による 第 8 回 サマーセミナーが2010 年 8 月 28 日 ( 土 ), 新 潟 大 学 有 壬 記 念 館 にて 開 催 されました. ワークショップ 肥 満 症 Q&A から 興 味 深 い 討 論 をいくつか 取 り 上 げ, 本 号
More information北アルプス_燕岳~穂高_-2.doc
1 ( )22 2001 2226 30 1300m 27kg 2 JR 1000 22 10 3 500-400 au 300 N 2763m 4 N N 10 N 500m PM9:00 5 ( 2 ) 7 23 2001 2226 10 N N 40 10 30 6 5m N N N 12 3 49 30 20 2922m 7 K ( ) U S N ( ) 50 15 N 35 (2758m)
More information164 Nanba Koji 120 DNA 2013 8 28 CM 1 1953 61 2 1956 41 3 1961 30 4 1955 112 2012 1937 85 /63 / 1937 /1955 /
164 Nanba Koji 120 DNA 2013 8 28 CM 1 1953 61 2 1956 41 3 1961 30 4 1955 112 2012 1937 85 /63 / 1937 /1955 / 165 5 1959 1963 30 5 6 1958 90 7 1958 90 8 1959 30 9 1959 20 10 1960 40 11 1962 30 12 1963 30
More informationM1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More informationuntitled
---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14
More information2
5 15.8% 17.1% 13.7% 15 1 34.0%3 1 3 25.7 4 1 76.5 3.3 2 23 3225 36 72.0 13.3 1 26 38 ( 77.8 87.8 69.5 2010 3 20 60 7 20 2 3 1 2 ( 77.8 87.8 69.5 2010 87.9 66.5 3 20 83.030 92.240 93.6 50 91.660 6065 72.9
More information12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
More information経済論集 46‐1(よこ)(P)/2.三崎
1 1 14 2 1866 8 20 20 2 4 1871 20 3 4 2 1969 9 12 28 33 3 1970 35 5 1965 p.119. 1995 p.67 1960 p.86. 1965 p.120. 1927 p.5. 1942 p.127, p.129. 10 1877 7 12 16 6 10 7 10 1877 8 7 6 8 16 25 29 10 1877 9 1
More informationPage () &
() () Page () & Page 110kg 67kg 138kg Page Page Page Page, Page () (S3)(S1 (S2) (S1) (S2)(S1) (S3) (S1) (A2)(A1) (A3)(S1) (S3)(S1) (A2)(A1) (A3)(A1) (A3) (A1) (S2) (S1) Page () 10 () () () () () () ()
More information<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
More information5. F(, 0) = = 4 = 4 O = 4 =. ( = = 4 ) = 4 ( 4 ), 0 = 4 4 O 4 = 4. () = 8 () = 4
... A F F l F l F(p, 0) = p p > 0 l p 0 P(, ) H P(, ) P l PH F PF = PH PF = PH p O p ( p) + = { ( p)} = 4p l = 4p (p 0) F(p, 0) = p O 3 5 5. F(, 0) = = 4 = 4 O = 4 =. ( = = 4 ) = 4 ( 4 ), 0 = 4 4 O 4 =
More informationt Z
t Z 1 11 1 1 1 1 1 1 1 1 1 1 1 1 UU 1 as a s 1 1 1 1 1 1 G q w e r q q w e r a s 1 1 1 1 1 1 1 a s a gg g q w e r 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
More information0
G 1 G 2 3 2 3 4 14 f f 0 G G G G a1 GF f 1 1 1 L I H M K J f 1 5 G G G G GG Aa G f 6 G G G Aa G f 1 2 1 2 3 45 C 123 3 4 1234 5 6 7 123 e 8 9 0 1 2 3 4 1 2 3 4 14 f N f f f 1 1 2 12 3 4 5 6 f 3 G G 1 12
More information宇都宮弁護士講演会 修正
2010 10 12 200 1,000 100 9 0.11 12 1 1946 1983 1970 KKC NHK 90 10 30 200 10 2 12 3 165 100 170cm 4 2 50 5 7 8 30 50 50 25 5 52 53 50 6 40 1965 2 3 7 3 4 8 8 4 8 2 1970 100 1970 10 20 10 20 8 2 2 9 1 10
More information717A 33 2 53 52B 429 430G 34 2005 5 5 2005 13 28 17 17 36 35 17 29 423G 424A 51A 7 41 7 54 5 59 51A4556 17 3 14 11 22 6 24 54 35 17 55 22 18 32 56F 57
Vol.13 CONTENTS P2.3s P4.5s P6.6s P7.7s P8.8s s 1 717A 33 2 53 52B 429 430G 34 2005 5 5 2005 13 28 17 17 36 35 17 29 423G 424A 51A 7 41 7 54 5 59 51A4556 17 3 14 11 22 6 24 54 35 17 55 22 18 32 56F 57G
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More information表紙030313.PDF
H2 CO (1) (3) (4) () () ( ) ( : 11 ) [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]......... [ ] [ ] [ ] [ ] [] [ ] [ ] [ ] [ ] (g) [ ] ) [ ] [ [ ] [ ] [ ] ) ) ) )... [ ] [] [ ] [] [ []........
More informationTRS4505.ec6..
糖尿病の療養指導 211 [ 日本糖尿病学会編 ] 別刷 レクチャー : 糖尿病療養指導に必要な知識 1 5 食後高血糖と脂質異常症の同時評価, 是正とその意義 原納 優, 前田亜耶, 名引順子, 原納晶著 211 年 9 月発行 発行所株式会社 診断と治療社 21 5 1 13 1,2 4 1 1 2 3 4 Key Words CMT Summary 154 CMT 1 IGT2 IFG3 1
More informationuntitled
1 Contents 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 2 1. 2. 3 3. 1 2 4 4. () () 5 4. 6 5. 7 6. 8 7. 1. 2. ( ) 3. 8 9 1. 1. 2. ( 2. (( ) ) 3. 3. 4. 4. 5. (PMV) ( ) 5. (PMV)( ) 6. 7. 20 1. 2. ( ) 3.
More information(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More information無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
More informationMicrosoft Word - 第2回海外勤務健康管理抄録の表紙他.doc
第 2 回 海 外 勤 務 者 健 康 管 理 研 修 会 平 成 19 年 3 月 10 日 ( 土 ) (14 時 ~17 時 ) ( 独 ) 労 働 者 健 康 福 祉 機 構 大 阪 労 災 病 院 管 理 棟 3F 大 ホール 591-8025 大 阪 府 堺 市 北 区 長 曾 根 町 1179 番 地 の3 共 催 ( 社 ) 大 阪 府 医 師 会 ( 社 ) 日 本 産 業 衛 生
More informationBUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
More information10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
More information1 食品安全を主な目的とする取組
--a 2003 7 26 3. 3.1-1- 16 2 27 0227012-2-a 23 7 1 82 2 1 7 9 2 ( ) -2- -2-b 19 3 28 18 14701-2-c ) 15 5 2-3- 26 21 7 2 2 7 2 3 7 2 4 10 83 23 3 1 7 2 5 7 2 5-2-d -4- -5 - -3-a -6- -4-a -7- -4-b -8- -5-a
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More information4 2 10 4 10 22 5 8 3 3 1. 2. 3. 4. 4 2
25 1 H25.11.20 1. 2. 3. 4. 5. 1 2 1 4 2 10 4 10 22 5 8 3 3 1. 2. 3. 4. 4 2 1. 2. 3., 4. 5 1. 1 2. 1 6 3 434 365 600 100 25 5 15 7 1 4200 8 4 9 ADI = ND 10 5 11 - NOEL NOAEL ADI 12 6 DNA 10 100 1 10-5 10-6
More informationレジャー産業と顧客満足の課題
1 1983 1983 2 3700 4800 5500 3300 15 3 100 1000 JR 4 14 2000 55% 72% 1878 2000 5 ( ) 22 1,040 5 946 42 15 25 30 30 4 14 39 1 24 8 6 390 33 800 34 34 3 35 () 37 40 1 50 40 46 47 2 55 4.43 4 16.98 40 55
More information